Novo to present 26 Wegovy and CagriSema abstracts at ObesityWeek, including real-world pill data
Novo will present 26 abstracts at ObesityWeek in Washington DC from 14 to 17 November, covering real-world Wegovy pill and injection use (including telehealth and food-noise studies), lower-dose CagriSema results and semaglutide in children aged 6 to under 12. One abstract looks at real-world semaglutide weight outcomes in the US and UK. This is a company announcement ahead of the data.
Source: Novo Nordisk via PR Newswire (29 Oct 2026). Image: Novo Nordisk via PR Newswire.